CYP2D6 phenotype and genotype in a Canadian native indian population

Pharmacogenetics

Volumn 7, Issue 2, 1997, Pages 145-148

  Nowak, Maciej P ^a   Tyndale, Rachel F ^a   Sellers, Edward M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP2D6; Dextromethorpan; North American Indian; Polymorphism

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE; DEXTROMETHORPHAN; DEXTRORPHAN; MITOCHONDRIAL DNA; MORPHINAN DERIVATIVE; SPARTEINE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CANADA; ENZYME POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CANADA; CHINA; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0030985006     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199704000-00008     Document Type: Article

References (10)

1. Arias TD. An observation on ethnic uniqueness of the debrisoquine and sparteine antimode: a study in the Ngawbe Guaymi Amerindians of Panama. Br J Pharmacol 1989: 28, 493-494.
2. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994: 4, 73-81.
3. Bertilsson L. Geographical/Interracial differences in polymorphic drug oxidation - current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokin 1995: 29, 192-209.
4. Broly F, Gaedigk A, Heim U, Eichelbaum M, Morike K, and Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in European populations. DNA Cell Biol 1991: 10, 545-557.
5. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, and Bertilsson L. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean. Japanese and Chinese subjects. Pharmacogenetics 1995: 5, 159-164.
6. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-532.
7. Johansson I, Oscarson M, Yue QY, Bertilsson L, Dahl M-L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450 2D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994: 46, 452-459.
8. Kupfer A, Schmid B, Preisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984: 2, 517-518.
9. Otton SV, Wu D, Joffe RT, Cheung SW and Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993: 53, 401-409.
10. Wallace DC and Torroni A. American Indian prehistory as written in the mitochondrial DNA: a review. Hum Biol 1992: 64, 403-416.